References
- European AIDS Clinical Society (EACS) guidelines. Version 6. EACS; 2011.
- Pérez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials 2002;3:279–86.
- Fumaz CR, Tuldrà A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 2002;29:244–53.
- Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, et al. Impact on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005;143:714–21.
- Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, et al. Treatment modification in human immune-deficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med2010;170:57–65.
- Dalgaard L, Soegaard OS, Jensen-Fangel S, Larsen CS, Sönnerborg A, Østergaard L. Use of InfCare HIV to identify and characterize suboptimally treated HIV patients at a Danish HIV clinic: a cross-sectional cohort study. Scand J Infect Dis 2012;44:108–14.
- Fumaz CR, Munoz-Moreno JA, Moltó J, Negredo E, Ferrer MJ, Sirera G, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychological issues, and adherence. J Acquir Immune Defic Syndr 2005;38:560–5.
- Rihs TA, Begley K, Smith DE, Sarangapany J, Callaghan A, Kelly M, et al. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med 2006;7:544–8.
- Vrouenraets SM, Wit FW, van Tongeren J, Lange JM. Efavirenz: a review. Expert Opin Pharmacother 2007;8:851–7.
- Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM; A5097s Study Team. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials 2009;10:343–55.
- Gutiérrez F, Navarro A, Padillo S, Antón R, Masiá M, Borrás J, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005;41:1648–53.
- Gatanaga H, Hayashida T, Tsuchiiya K, Yoshino M, Kuwahara T, Tsukada H, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007;45:1230–7.
- Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS 2006;20:542–8.
- Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naïve patients: a systematic review. AIDS Rev 2010:12:67–75.
- Waters L, Fischer M, Winston A, Higgs C, Hadley C, Garvey L, et al. A phase IV, double-blind, multicentre, randomized, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 2011;25:65–71.
- Nguyen A, Calmy A, Delhumeau C, Mercier I, Cavassini M, Mello AF, et al. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS 2011;25:57–63.
- Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Pilpivirine versus efavirenz and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011;378:238–46.
- Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine versus efavirenz with two backbone nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011;378:229–37.
- Nelson M, Stellbrink HJ, Podzamczer D, Banhegyi D, Gazzard B, Hill A, et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS 2011;25:335–40.
- Petersen T, Andersen SE, Gerstoft J, Thorsteinsson K, Larsen CS, Pedersen G, et al. Adherence to national guidelines for initiation of antiretroviral regimens in HIV patients: a Danish nationwide study. Br J Clin Pharmacol 2011;72:116–24.